Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
115 results about "COX-2 inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Selective COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration, and is the main feature of celecoxib, rofecoxib and other members of this drug class.
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.
Owner:PHARMACIA CORP
Water soluble prodrugs of COX-2 inhibitors
Disclosed are water soluble compounds which are useful as prodrugs of COX-2 inhibitors, and pharmaceutical compositions comprising them.
Owner:MERCK & CO INC
Endometriosis treatment protocol
The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.
Owner:SHIPPEN EUGENE R
Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
InactiveUS20050227929A1Effective amountReduce dosageBiocideSomatostatinsCOX-2 inhibitorCombination therapy
A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising a Cox-2 inhibitor and an antineoplastic agent.
Owner:PHARMACIA & UPJOHN CO
Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
A compound of the formulawhere:n, andX are as defined in the specification,and the compound possesses selectivity for inhibition of cyclooxygenase-2.
Owner:VANDERBILT UNIV
C-nitroso compounds and use thereof
InactiveUS6887994B2Inhibition productionReduce impactAntibacterial agentsOrganic chemistryNitrosoNo donors
A C-nitroso compound having a molecular weight ranging from about 225 to about 1,000 (from about 225 to about 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. In another case, the C-nitroso compound contains the moiety—C—N(O)X—where X is S, O or NR. One embodiment is directed to COX-2 inhibitors where a tertiary carbon atom and / or an oxygen atom and / or a sulfur atom is nitrosylated.
Owner:DUKE UNIV
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
InactiveUS20080153894A1Effectively treat painMinimal to no irritationAntibacterial agentsBiocideCOX-2 inhibitorMastitis
A method is provided for treatment of an infective condition in an udder of a milk producing animal. The method comprises intramammary administration of an antibacterial agent in combination therapy with a selective COX-2 inhibitor in therapeutically effective amounts of each. Also provided is a pharmaceutical composition comprising an antibacterial agent and a selective COX-2 inhibitor, together with one or more excipients, in a dosage form suitable for intramammary administration to a milk producing animal.
Owner:PHARMACIA CORP
Therapeutic combinations for cardiovascular and inflammatory indications
InactiveUS20030199482A1Eliminate side effectsImprove complianceBiocideOrganic chemistryCOX-2 inhibitorEnzyme inhibitor
The present invention provides therapeutic combinations and methods for treating or preventing a hypercholesterolemia-related or an inflammation-related condition in a subject in need of such treatment or prevention. One therapeutic combination comprises an ASBT inhibitor combined with COX-2 inhibitor. A further therapeutic combination comprises an ASBT inhibitor, a COX-2 inhibitor and an HMG Co-A reductase inhibitor. Another therapeutic combination comprises a chromene COX-2 inhibitor and an HMG Co-A reductase inhibitor.
Owner:PHARMACIA CORP
Methods and compositions for treatment of inflammatory disease
InactiveUS7112578B2Promote absorptionProtect normal developmentBiocidePeptide/protein ingredientsArthritisCytokine
Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.
Owner:LEVIN BRUCE H
Method of Improving Treatments in Rheumatic and Arthritic Diseases
Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and / or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors / antagonists of IL-1, inhibitors / antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors / antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and / or prophylactically active substance as defined above.
Owner:OSTEOLOGIX AS
Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
Owner:PHARMACIA CORP
Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier.
Owner:UNIGEN
COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
InactiveUS20110306572A1Convenient treatmentEliminate side effectsBiocideCarbohydrate active ingredientsCOX-2 inhibitorDual inhibitor
Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.
![COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]](https://images-eureka.patsnap.com/patent_img/7d747034-9d90-4174-886e-db10a0026f30/US20110306572A1-20111215-D00001.png "COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]")
![COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]](https://images-eureka.patsnap.com/patent_img/7d747034-9d90-4174-886e-db10a0026f30/US20110306572A1-20111215-C00001.png "COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]")
![COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]](https://images-eureka.patsnap.com/patent_img/7d747034-9d90-4174-886e-db10a0026f30/US20110306572A1-20111215-C00002.png "COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]")
Owner:TRAGARA PHARMA INC
Method and compositions for the treatment and prevention of pain and inflammation
InactiveUS20050101563A1Selective in their physiological impactBiocideSenses disorderCOX-2 inhibitorChondroitin
A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and / or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and / or chondroitin, are disclosed, as are pharmaceutical compositions.
Owner:PHARMACIA CORP
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
InactiveUS20050119262A1Efficacious and safe and easy to administerBiocideElcosanoid active ingredientsIntraocular pressureCOX-2 inhibitor
The present invention provides methods and compositions for the prevention and / or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent.
Owner:PHARMACIA CORP
Methods and compositions for treatment of inflammatory disease
InactiveUS20070020254A1Protect normal developmentReduce the amount requiredBiocidePeptide/protein ingredientsArthritisCytokine
Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.
Owner:LEVIN BRUCE
Therapeutic compositions
InactiveUS20070098800A1Less destructiveFew other adverse effectPowder deliveryNervous disorderJoint painIntraarticular Injections
The present invention provides new formulations of injectable particles (e.g. microspheres) useful for intra-articular (i.a.) injection. The formulations are made of biocompatible polymers that biodegrade to generate NSAIDs, ad are useful for treating inflamed joints, thus providing safe, long-lasting relief of joint pain and swelling. In one embodiment, the present invention provides an injectable particle, comprising a biodegradable polymer comprising an agent selected from the group consisting of an NSAID, a COX-2 inhibitor, an anesthetic and a narcotic analgesic.
Owner:HYDRO QUEBEC CORP +1
N2S2 chelate-targeting ligand conjugates
ActiveUS20050129619A1Sufficient amountHybrid immunoglobulinsRadioactive preparation carriersAngiostatinAbnormal tissue growth
The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
COX-2 and FAAH inhibitors
Owner:IRONWOOD PHARMA
Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
InactiveUS20080199484A1Good treatment effectOrganic active ingredientsSnake antigen ingredientsT lymphocyteWilms' tumor
The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifically, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer. The COX-2 inhibitors of the present invention are believed to inhibit the enzymatic activity of prostaglandineE2 (PGE2); thereby preventing COX-2 overexpressing tumors from evading immune surveillance by antigen-specific cytotoxic T lymphocytes (CTLs). COX-2 inhibitors are believed to suppress PGE2 that COX-2 overexpressing glioma produce, allowing tumor-infiltrating DCs to polarize Th cells toward Th-subset-1 (Th1).
Owner:CEDARS SINAI MEDICAL CENT
Combination therapy of arthritis with tranilast
InactiveUS20100158905A1Good treatment effectAntibacterial agentsSalicyclic acid active ingredientsCombined Modality TherapyCOX-2 inhibitor
Combination therapy is disclosed herein for the treatment an arthritic condition (e.g. rheumatoid arthritis, osteoarthritis or psoriatic arthritis). The therapies disclosed herein comprise administering tranilast or an analogous compound in combination with a pharmaceutical agent, such as a non-steroidal anti-inflammatory drug, a disease-modifying drug, a COX-2 inhibitor, an antibiotic, an analgesic or combination thereof.
Owner:NUON THERAPEUTICS INC
Soft shell gelatin capsules containing non-steroidal anti-inflammatories
InactiveUS6689382B2Rapid onset of pharmacologic actionAccurate and uniform deliveryBiocideCapsule deliveryFenamic acidSoftgel
Owner:PROCAPS
Anti cancer combinations comprising a cox-2 inhibitor
InactiveUS20070082937A1Improve efficiencyOrganic active ingredientsBiocideAcetic acidCOX-2 inhibitor
The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing said combinations.
Owner:CANCER RES TECH LTD
Pharmaceutical combinations of cox-2 inhibitors and opiates
ABSTRACTA pharmaceutical composition comprises a combination of a selective or specific COX 2 inhibitor or a pharmaceutically acceptable salt or derivative thereof and an opiate or a pharmaceutically acceptable salt or derivative thereof, for example a combination of meloxicam and codeine, as active ingredients, and a pharmaceutically acceptable carrier. It may include a centrally-acting cyclo-oxygenase inhibitor such as paracetamol or its pharmaceutically acceptable salts or derivatives. The pharmaceutical compositions are used in methods of providing symptomatic relief or treatment of pain, in an algesic and / or hyperalgesic state, with or without fever, in particular that associated with inflammation such as that associated with trauma, osteoarthritis, rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea
Owner:ADCOCK INGRAM LTD
Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier.
Owner:UNIGEN
Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor
InactiveUS20060217431A1Inhibit platelet activationPrevents vasoconstrictive actionBiocideNervous disorderDiseaseCOX-2 inhibitor
The invention relates to a pharmaceutical composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor. In addition a method of treating cyclooxygenase dependent disorders, including inflammation, pain and / or rheumatic diseases, and / or neoplasia is described.
Owner:BOEHRINGER INGELHEIM INT GMBH
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
InactiveUS20050187278A1Efficacious and safe and easy to administerBiocideAmide active ingredientsCOX-2 inhibitorPhosphodiesterase inhibitor
A method is described for the prevention and / or treatment of vascular disorders and vascular disorder-related complications in a subject, the method comprising administering to the subject a Cox-2 inhibitor in combination with a cAMP-specific PDE inhibitor. Also described are therapeutic and pharmaceutical compositions and kits that are useful in the present invention.
Owner:PHARMACIA CORP
Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.
Owner:PHARMACIA CORP
Process for making substituted pyrazoles
Owner:PHARMACIA CORP
Cardiac hormones for assessing cardiovascular risk
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com